Effects of arsenite exposure during fetal development on energy metabolism and susceptibility to diet-induced fatty liver disease in male mice

Background: Chronic exposure to arsenicals at various life stages and across a range of exposures has been implicated in cardiometabolic and liver disease, but disease predisposition from developmental exposures remains unclear. Objectives: In utero and post-weaning exposure to trivalent arsenic (As^III) was examined on the background of a Western-style diet to determine whether As^III exposure affects metabolic disease. Methods: Male Swiss Webster mice were exposed to 100 ppb As^III in utero, after weaning, or both. Ad libitum access to a Western-style diet was provided after weaning, and the plasma metabolome, liver histopathology, liver enzyme activity, and gene expression were analyzed. Results: Hepatic lipid composition and histopathology revealed that developmental As^III exposure exacerbated Western-style diet–induced fatty liver disease. Continuous As^III exposure increased cardiometabolic risk factors including increased body weight, insulin resistance, hyperglycemia, and plasma triglycerides. As^III exposure produced a decrease in the intermediates of glycolysis and the TCA cycle while increasing ketones. Hepatic isocitrate dehydrogenase activity was also decreased, which confirmed disruption of the TCA cycle. Developmental As^III exposure increased the expression of genes involved in fatty acid synthesis, lipogenesis, inflammation, and packaging of triglycerides, suggesting an increased acetyl coenzyme A (acetyl-CoA) load. Conclusions: In utero and continuous early-life exposure to As^III disrupted normal metabolism and elevated the risk for fatty liver disease in mice maintained on a high-fat diet. Our findings suggest that individuals exposed to As^III during key developmental periods and who remain exposed to As^III on the background of a Western-style diet may be at increased risk for metabolic disease later in life.